Management of Intraoperative Fluids in Ambulatory Surgery (MIFAS)
Intraoperative Fluid Therapy Management in Low-risk Patients Under General Anesthesia- a Randomized Controlled Trial Comparing Liberal, Restrictive and Pleth Variability Index (PVI)-Guided Fluid Administration in a Day Surgery Setting
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Forventet)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Renzo G Di Natale, MD
- Telefonnummer: +584122715908
- E-post: renzogdg@gmail.com
Studiesteder
-
-
Miranda
-
Caracas, Miranda, Venezuela, 01061
- Policlinica Metropolitana
-
Ta kontakt med:
- Telephone central
- Telefonnummer: +582129080100
-
Hovedetterforsker:
- Pascual M Carucci, MD
-
Underetterforsker:
- Renzo G Di Natale, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- participants attending the unit for a day surgery procedure
- participants whose surgeries will be performed under general anesthesia
- aged between 18-65 years
- no abnormal findings on chest x-ray or electrocardiogram on preoperative evaluation
- patients undergoing procedures which do not require opening of the abdominal or thoracic cavities
Exclusion Criteria:
- ASA score III or higher
- patients undergoing surgeries which require additional pain management procedures (e.g. selective nerve blockade, epidural anesthesia, etc.)
- known pregnant women
- known kidney disease (or serum creatinine >1.8 mg/dl)
- known liver disease (or AST/ALT >60 U/l)
- known chronic heart failure (determined by a LVEF <55%)
- participants who develop hypotension intraoperatively and do not respond to 4 fluid challenges (1000 ml), requiring aggressive fluid resuscitation OR vasopressors
- estimated blood loss during surgery >250 ml
- development of an adverse reaction to any of the drugs administered during surgery (requiring additional medical management)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Aktiv komparator: Liberal group protocol
Fluid loading with 500 ml at induction.
Baseline fluid infusion - 8 ml/kg/h.
Fluid challenge - if mean arterial pressure (MAP) falls to < 65 mmHg, a fluid challenge will be administered.
|
Only ringer lactate (RL solution will be used).
1. Fluid loading at induction with 500 ml of ringer lactate solution will be given to some groups.
2. Base infusion rate varies according to group.
3. Fluid challenges - infusion of 250 ml over 5 min, a hemodynamic parameter specific to each group will be monitored for 10 min after the end of infusion to look for changes.
Patients who do not respond to four (4) fluid challenges (volume infused 1000 ml) will be excluded.
|
|
Aktiv komparator: Restrictive group protocol
No fluid loading at induction.
Baseline fluid infusion - 4 ml/kg/h.
Fluid challenges - if mean arterial pressure (MAP) falls to < 65 mmHg, a fluid challenge will be administered.
|
Only ringer lactate (RL solution will be used).
1. Fluid loading at induction with 500 ml of ringer lactate solution will be given to some groups.
2. Base infusion rate varies according to group.
3. Fluid challenges - infusion of 250 ml over 5 min, a hemodynamic parameter specific to each group will be monitored for 10 min after the end of infusion to look for changes.
Patients who do not respond to four (4) fluid challenges (volume infused 1000 ml) will be excluded.
|
|
Eksperimentell: PVI-guided group protocol
No fluid loading at induction.
Baseline fluid infusion - 2 ml/kg/h.
PVI will be monitored continuously since anesthesia induction.
Fluid challenges - if PVI rises >=13 (or MAP falls < 65 mmHg), a fluid challenge will be administered.
|
Only ringer lactate (RL solution will be used).
1. Fluid loading at induction with 500 ml of ringer lactate solution will be given to some groups.
2. Base infusion rate varies according to group.
3. Fluid challenges - infusion of 250 ml over 5 min, a hemodynamic parameter specific to each group will be monitored for 10 min after the end of infusion to look for changes.
Patients who do not respond to four (4) fluid challenges (volume infused 1000 ml) will be excluded.
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Total volume of fluid infused intraoperatively
Tidsramme: 0 min after extubation
|
Total volume of ringer lactate solution infused intraoperatively to participants (ml).
|
0 min after extubation
|
|
Time to discharge
Tidsramme: 240 min after extubation (discharge)
|
Time in hours (h) from anesthesia reversal to fulfillment of patient discharge criteria.
Patients will be assessed by an attending nurse every 30 min to assess the fulfillment of these criteria.
|
240 min after extubation (discharge)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Significant postoperative nausea and vomiting (PONV)
Tidsramme: 240 min after extubation (discharge)
|
Presence of significant PONV as determined by a score ≥5 on the scale proposed by Myles SA et al. (BJA 2012)
|
240 min after extubation (discharge)
|
|
Postoperative dizziness
Tidsramme: 30 min after reversal
|
Presence of patient self-reported dizziness in the post-operative period.
|
30 min after reversal
|
|
Postoperative fatigue
Tidsramme: 30 min after reversal
|
Presence of patient self-reported fatigue after surgery.
|
30 min after reversal
|
|
Postoperative thirst
Tidsramme: 30 min after reversal
|
Presence of patient self-reported thirst after surgery
|
30 min after reversal
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Studieleder: Pascual M Carucci, MD, Policlinica Metropolitana
Studierekorddatoer
Studer hoveddatoer
Studiestart (Forventet)
Studiestart
Primær fullføring (Forventet)
Primær fullføring
Studiet fullført (Forventet)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
Andre studie-ID-numre
- 1701
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .